Until now, several SHP-2 allosteric inhibitors, such as JAB-3068, JAB-3312, TNO155, ERAS-601, RMC-4630, BBP-398, SH3809, RLY-1971, and HBI-2376, have advanced into clinical trials for cancer treatment [58]. The gene discussed is PTPN11; the disease is cancer.